Compare iSERA Lifescienc with Similar Stocks
Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 136.00% and Operating profit at 0% over the last 5 years
- The company has a negative book value of Rs 0.11 crore
Flat results in Jun 26
Risky - Negative Book Value
Total Returns (Price + Dividend) 
Latest dividend: 166.66672025723472 per share ex-dividend date: Sep-20-2013
Risk Adjusted Returns v/s 
Returns Beta
News

Covidh Technologies Ltd is Rated Sell
Covidh Technologies Ltd is rated Sell by MarketsMOJO. This rating was last updated on 03 Jul 2025, but the analysis below reflects the stock’s current position as of 30 July 2026, incorporating the latest fundamentals, returns, and financial metrics available today.
Read full news article
Covidh Technologies Ltd is Rated Sell
Covidh Technologies Ltd is rated 'Sell' by MarketsMOJO, a rating that was established on 03 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 19 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article Announcements 
Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026 Under Regulation 30 Of SEBI
07-Aug-2026 | Source : BSEUn-Audited Financial Results For The Quarter Ended June 30 2026
07-Aug-2026 | Source : BSEWe are hereby submitting the Unaudited Financial Results of the Company for the quarter ended June 30 2026.
Board Meeting Intimation for The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Friday 7 August 2026 Inter-Alia To Consider Approve And Take On Record The Unaudited Financial Results Of The Company For The Quarter Ended On J
03-Aug-2026 | Source : BSEIsera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended on June 30 2026
Corporate Actions 
No Upcoming Board Meetings
iSERA Lifesciences Ltd has declared 5% dividend, ex-date: 20 Sep 13
No Splits history available
No Bonus history available
iSERA Lifesciences Ltd has announced 25:1 rights issue, ex-date: 24 Oct 25
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Dhairyasheel Vasantrao Yadav (13.26%)
Neville Maneckji (4.31%)
35.4%
Quarterly Results Snapshot (Standalone) - Jun'26 - YoY
YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025
YoY Growth in quarter ended Jun 2026 is -1,600.00% vs -100.00% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 50.00% vs 33.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -222.22% vs 75.68% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025
YoY Growth in year ended Mar 2026 is 116.67% vs 220.00% in Mar 2025







